July 21, 2026 | Health Care | North America | Active
On 6-Jul-26, Crinetics Pharmaceuticals, an endocrine disease-focused biopharma, agreed to be acquired by Vertex Pharmaceuticals, a dominant biotech in cystic fibrosis (CF) drugs. Under the terms of this $10bn all-cash agreed deal, Vertex is offering $85.00 per Crinetics share, representing a 102.2% one-day premium. Vertex will fund the deal through it existing cash and debt, and it has secured fully committed bridge financing for $4.5bn from Bank of America and Morgan Stanley. The deal is subject to Crinetics shareholder approval (50%) and regulatory clearances, including HSR and unspecified foreign regulatory approvals. To date, the companies have filed with German and Austrian antitrust regulators on 10-Jul-26 and 14-Jul-26, respectively, implying an EU-wide notification may not be required. The merger agreement’s MAC contains carve-outs for force majeure events, including tariffs, war, and pandemic, as well as drug trial outcomes. A standard non-solicitation restriction with a fiduciary-out exemption applies only to Crinetics. Both parties agree to use reasonable best efforts to take all actions necessary to obtain regulatory approvals and close the deal, and the burdensome condition restricts offering any remedies relating to businesses of Vertex or, in the case of remedies relating to the business or assets of Crinetics, if such remedy would be material and adverse to Crinetics. Any remedy that is offered must, in any event, be conditioned on completion of the merger. A preliminary proxy as well as an HSR notification will be filed within ...
Contents
Please contact us to request access to this report.